## West of Scotland NEONATAL Parenteral Drug Monographs

# **Enoxaparin**

**FORM** Pre-filled syringe containing 20mg in 0.2ml

**INDICATION** 1) Treatment of thrombotic episode

2) Prophylaxis of thrombotic episode

#### **DOSE RANGE**

#### 1) TREATMENT of thrombotic episode

AGE	DOSE	FREQUENCY	ROUTE
< 2 months	2mg/kg	Twice daily	s/c
2 – 6 months	1mg/kg	Twice daily	s/c

#### 2) PROPHYLAXIS of thrombotic episode

AGE	DOSE	FREQUENCY	ROUTE
< 2 months	0.75mg/kg	Twice daily	s/c
2 – 6 months	0.5mg/kg	Twice daily	s/c

**RECONSTITUTION** Not required

**DILUTION** Enoxaparin 20mg/0.2ml 0.2ml

Water for injection up to 2ml total

This gives a 10mg/ml solution. Use required volume

Doses greater than 5mg should be given undiluted as the maximum

recommended subcutaneous volume for a neonate is 0.5ml.

METHOD OF

**ADMINISTRATION** Subcutaneous injection.

Do not mix with any other injections or infusions

### CAUTIONS, CONTRA-INDICATIONS AND SIDE EFFECTS

- See Summary of Product Characteristics and most recent edition of BNF for Children (links below)

Meomatall

Enoxaparin\_IVWOSNeo Page 1 of 2

### West of Scotland NEONATAL Parenteral Drug Monographs

#### **MONITORING**

Check a heparin assay 4 hours post dose.

Target treatment range = 0.5 - 1.0 u/ml Target prophylactic range = 0.3 - 0.5 u/ml

Enoxaparin <u>Treatment Dose</u> Adjustments based on monitoring results (Table from Paediatric Thromboembolism and Stroke protocols, Maureen Andrew)

Heparin Assay (units/ml)	Enoxaparin Dose Adjustment	Subsequent monitoring
<0.35	Increase by 25%	4 hours post next dose
0.35 - 0.49	Increase by 10%	4 hours post next dose
0.5 - 1	Not required	Weekly (4hrs post dose)
> 1 – 1.5	Decrease by 20%	4 hours post next dose
>1.5 - 2	Decrease by 30%	4 hours post next dose
> 2	Hold all further doses and measure heparin assay every 12 hours until the result is <0.5units/ml.  Then restart enoxaparin at 40% less than previous dose.	

NB. The advice in this table assumes there is no bleeding

#### **FURTHER INFORMATION**

- Avoid using multidose vial as this contains benzyl alcohol
- Enoxaparin sodium 20 mg is equivalent to 2,000 IU anti-Xa activity

LICENSED STATUS Unlicensed use

LINKS BNF for Children: / Electronic Medicines Compendium

APPLICABLE POLICIES West of Scotland Neonatal Guidelines:

Consult local policy if applicable

Document Number:	003	Supersedes:	002
Prepared by:	WoS Neo pharm group	Checked by	Michael Mitchell
Date prepared	May 2016	Date Updated	February 2020
Updated by	Anisa Patel	Review Date	February 2023

Administer reconstituted solutions immediately.

All vials, ampoules and infusion bags are for single use only unless otherwise stated.

Dose may vary depending on indication, age, renal function, hepatic function, and concomitant medications. This monograph should be used in conjunction with the package insert, BNF for Children, and Summary of Product Characteristics. For further advice contact your clinical pharmacist or pharmacy department.

Enoxaparin\_IVWOSNeo Page 2 of 2